Budget Impact of Niraparib As Maintenance Treatment for Medicare Patients with Recurrent Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Who are in Complete or Partial Response to Platinum-Based Chemotherapy
Abstract
Authors
K Neeser WM O'Neil L Stern